International Journal of Endocrinology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894262, encodeId=52f589426272, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e664732726, createdName=lau0325, createdTime=Sun Oct 25 10:29:37 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570360, encodeId=2da45e0360bd, content=大修了之后小修，还会被拒吗？返回去一周了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu May 02 19:59:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

2023-10-18 ms1000001042631374 来自江西省

偏重的研究方向：糖尿病;临床
经验分享：15天还在AE invited....

25 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894262, encodeId=52f589426272, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e664732726, createdName=lau0325, createdTime=Sun Oct 25 10:29:37 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570360, encodeId=2da45e0360bd, content=大修了之后小修，还会被拒吗？返回去一周了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu May 02 19:59:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

2023-12-19 12112347m62(暂无昵称) 来自浙江省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：甲状腺
经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~

22 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894262, encodeId=52f589426272, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e664732726, createdName=lau0325, createdTime=Sun Oct 25 10:29:37 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570360, encodeId=2da45e0360bd, content=大修了之后小修，还会被拒吗？返回去一周了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu May 02 19:59:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

2022-03-17 14755044m78暂无昵称

大家的reviewer invited 都持续了多久啊请问

76 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894262, encodeId=52f589426272, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e664732726, createdName=lau0325, createdTime=Sun Oct 25 10:29:37 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570360, encodeId=2da45e0360bd, content=大修了之后小修，还会被拒吗？返回去一周了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu May 02 19:59:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

2022-03-10 14755044m78暂无昵称

请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！

40 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894262, encodeId=52f589426272, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e664732726, createdName=lau0325, createdTime=Sun Oct 25 10:29:37 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570360, encodeId=2da45e0360bd, content=大修了之后小修，还会被拒吗？返回去一周了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu May 02 19:59:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

2020-10-25 lau0325

审稿速度:1.0 | 投稿命中率:50.0
经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。

85 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894262, encodeId=52f589426272, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e664732726, createdName=lau0325, createdTime=Sun Oct 25 10:29:37 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570360, encodeId=2da45e0360bd, content=大修了之后小修，还会被拒吗？返回去一周了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu May 02 19:59:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

2019-05-02 1e16a6dfm27(暂无匿称)

大修了之后小修，还会被拒吗？返回去一周了，还没有消息。

152 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894262, encodeId=52f589426272, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e664732726, createdName=lau0325, createdTime=Sun Oct 25 10:29:37 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570360, encodeId=2da45e0360bd, content=大修了之后小修，还会被拒吗？返回去一周了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu May 02 19:59:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

2024-04-01 ms8000000748328144 来自云南省

被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，

8 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894262, encodeId=52f589426272, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e664732726, createdName=lau0325, createdTime=Sun Oct 25 10:29:37 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570360, encodeId=2da45e0360bd, content=大修了之后小修，还会被拒吗？返回去一周了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu May 02 19:59:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

2022-07-07 ms8000001001905278

有人知道现在得版面费是多少吗

51 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894262, encodeId=52f589426272, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e664732726, createdName=lau0325, createdTime=Sun Oct 25 10:29:37 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570360, encodeId=2da45e0360bd, content=大修了之后小修，还会被拒吗？返回去一周了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu May 02 19:59:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

2022-05-10 ms8000001987505662

这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛

46 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向：糖尿病;临床 经验分享：15天还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：2023年6月中旬投稿，10月初一审给大修，11月下旬返修后显示under review，两周后变成pending approval，到目前持续了16天了没有改变，不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1203507, encodeId=2b1d120350efc, content=大家的reviewer invited 都持续了多久啊请问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 17 17:11:15 CST 2022, time=2022-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201451, encodeId=56b312014519f, content=请问大家，这篇杂志是一开始投进去就查重，还是审稿完PENDING APPROVAL阶段查重?谢谢答复！！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee965208520, createdName=14755044m78暂无昵称, createdTime=Thu Mar 10 17:08:15 CST 2022, time=2022-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894262, encodeId=52f589426272, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：请问大家，缴版面费的邮件会发给一作吗？还是只发给通讯作者？临床型文章：一审1个月提了很多问题，一个月修改回复后2w接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e664732726, createdName=lau0325, createdTime=Sun Oct 25 10:29:37 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570360, encodeId=2da45e0360bd, content=大修了之后小修，还会被拒吗？返回去一周了，还没有消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=152, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35fa1974274, createdName=1e16a6dfm27(暂无匿称), createdTime=Thu May 02 19:59:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2196503, encodeId=b8d521965034f, content=被Clinical endocrinology 推荐转投，我同意了，，请问又从哪里登录查看稿件动态呢？小白求帮助，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc559038572, createdName=ms8000000748328144, createdTime=Mon Apr 01 20:42:36 CST 2024, time=2024-04-01, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=1231223, encodeId=3ef31231223eb, content=有人知道现在得版面费是多少吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f98204009, createdName=ms8000001001905278, createdTime=Thu Jul 07 23:20:21 CST 2022, time=2022-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218470, encodeId=c70712184e08d, content=这个和International Journal of Endocrinology Research and Reviews(IJERR)是一个期刊嘛 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2916563456, createdName=ms8000001987505662, createdTime=Tue May 10 15:43:27 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067768, encodeId=8d4f106e76855, content=我已经五个月了，一直是under review，正常吗，在线等，要等哭了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43585514003, createdName=ms4000001135259825, createdTime=Sun Nov 07 11:20:36 CST 2021, time=2021-11-07, status=1, ipAttribution=)]

2021-11-07 ms4000001135259825

我已经五个月了，一直是under review，正常吗，在线等，要等哭了。

50 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务